Eine groß angelegte, multizentrische Doppelblindstudie mit Ursodeoxycholsäure bei Patienten mit chronischer Hepatitis C

A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C

Herunterladen - PDF

Abstract

Background:

Combined pegylated interferon and ribavirin has improved chronic hepatitis C(CH-C) therapy; however, sustained virological response is achieved in only about half of thepatients with a 1b genotype infection. We assessed oral ursodeoxycholic acid (UDCA) onserum biomarkers as a possible treatment for interferon non-responders.

Methods:

CH-C patients with elevated alanine aminotransferase (ALT) were assignedrandomly to 150 (n = 199), 600 (n = 200) or 900 mg/day (n = 197) UDCA intake for 24 weeks.Changes in ALT, aspartate aminotransferase (AST) and gamma-glutamyl transpeptidase (GGT)were assessed. This study is registered at ClinicalTrial.gov, identifier NCT00200343.

Results:

ALT, AST and GGT decreased at week 4 and then remained constant during drugadministration. The median changes (150, 600 and 900 mg/day, respectively) were: ALT, -15.3,-29.2 and -36.2%; AST, -13.6, -25.0 and -29.8%; GGT, -22.4, -41.0 and -50.0%. Thesebiomarkers decreased significantly less in the 150 mg/day than in the other two groups.Although changes in ALT and AST did not differ between the 600 and 900 mg/day groups, GGTwas significantly lower in the 900 mg/day group. In subgroup analysis, ALT decreasedsignificantly in the 900 mg/day group when the baseline GGT exceeded 80 IU/l. Serum HCV-RNA did not change in any group. Adverse effects were reported by 19.1% of the patients, withno differences between groups.

Conclusion:

A 600 mg/day UDCA dose was optimal to decrease ALT and AST levels inCH-C patients. The 900 mg/day dose decreased GGT levels further, and may be preferable inpatients with prevailing biliary injuries.

Source:https://www.ncbi.nlm.nih.gov/pubmed/17573387 – 2007

gallmet.hu
de_DE_formalDeutsch (Sie)
Überblick über den Datenschutz
gallmet.hu

Diese Website verwendet Cookies, um Ihnen die bestmögliche Benutzererfahrung zu bieten. Cookie-Informationen werden in Ihrem Browser gespeichert und dienen dazu, Sie wiederzuerkennen, wenn Sie auf unsere Website zurückkehren, und unserem Team zu helfen, zu verstehen, welche Bereiche der Website Sie am interessantesten und nützlichsten finden.

Streng notwendige Cookies

Strictly Necessary Cookie sollte immer aktiviert sein, damit wir uns Ihre Präferenzen für Cookie-Einstellungen merken können.

Cookies von Dritten

Diese Website sammelt anonyme Informationen durch die Verwendung von Cookies von Dritten (werbebezogene Cookies und Performance-Cookies)